Related Experiment Video
Updated: Apr 6, 2026
02:49
Author Spotlight: A Multi-Depth Porcine Model for Comprehensive Study of Burn Injuries and Healing Processes
Published on: February 23, 2024
2.3K
Do β-Blockers Decrease the Hypermetabolic State in Critically Ill Children With Severe Burns?
Elaine Chu Shan Chew1, Nicole Baier2, Jan Hau Lee3
1Department of Paediatric Medicine, and chewchushan@gmail.com.
Hospital Pediatrics
|August 2, 2015
Summary
Short-term beta-blockers may reduce the hypermetabolic state in pediatric burn patients, improving lean muscle mass. However, evidence does not yet support a reduction in mortality or length of stay (LOS) for severe burns.
Area of Science:
- Burn injury research
- Pharmacological interventions
- Metabolic response to trauma
Background:
- Severe burns induce a hypermetabolic state, increasing patient morbidity and mortality.
- Understanding interventions to mitigate this response is crucial for improving outcomes.
- Beta-blockers are investigated for their potential to modulate the hypermetabolic state.
Purpose of the Study:
- To evaluate the efficacy of short-term beta-blocker therapy in severe burn patients.
- To determine the impact of beta-blockers on the hypermetabolic state, mortality, and length of stay (LOS).
- To assess the strength of evidence from existing literature.
Main Methods:
- Systematic literature search across major databases (PubMed, Embase, Cochrane).
- Inclusion of randomized controlled trials (RCTs) investigating beta-antagonists in burn patients.
- Analysis of outcomes including metabolic markers, LOS, and mortality.
Main Results:
- Five pediatric RCTs indicated beta-blockers reduced markers of the hypermetabolic state and improved lean muscle mass.
- No significant changes in LOS or mortality were observed in pediatric patients.
- One adult study reported a shorter LOS with beta-blocker use, but no mortality difference.
- Beta-blockers were generally well-tolerated with no increased adverse effects.
Conclusions:
- Beta-blockers show promise in mitigating the hypermetabolic state in pediatric burn survivors.
- Current evidence is insufficient to confirm a benefit of beta-blockers on mortality rates or LOS in severe burn patients.
- Further research is needed to clarify the role of beta-blockers in burn management.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
1.9K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.9K
01:22Heart Failure Drugs: β-Blockers
1.2K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
01:28Antihypertensive Drugs: Types of β-Blockers
2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
341
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
341
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
2.3K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.3K